Endo International | ENDP - Sales Revenues


Endo International reported $497.73M in Sales Revenues for its fiscal quarter ending in December of 2023.



Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Amarin USD 49.22M 451K Dec/2025
ANI Pharmaceuticals USD 247.06M 19.25M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Takeda JPY 1.19T 80B Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Xeris Pharmaceuticals USD 85.81M 11.43M Dec/2025
Zoetis USD 2.4B 0 Dec/2025